# Mentorship in Investigating Novel Risk Models and Prognostic Factors in Patients Less Than 21 Years Old with Venous Thromboembolism

> **NIH NIH K24** · JOHNS HOPKINS UNIVERSITY · 2024 · $128,799

## Abstract

ABSTRACT
Venous thromboembolism (VTE), consisting of deep vein thrombosis (DVT) and pulmonary embolism (PE),
affects approximately 1 in 200 hospitalized patients <21 years old, and annual health care costs of pediatric VTE
can be estimated at $72M in the U.S. alone. As in adults, PE can be fatal in pediatric patients, and DVT can
result in long-term chronic venous insufficiency (the post-thrombotic syndrome [PTS]). However, treatment and
prevention of VTE with anticoagulant medications carries a risk for bleeding, which can be life-threating. In order
to optimize net clinical benefit, pediatric subpopulation-specific risks assessment models (RAMs) must be
developed and validated, and prognostic factors identified, in patients <21 years old. This has been the focus of
my career-long research work and mentorship. Recently, my multinational collaborators and I have made
significant advances in pediatric VTE treatment via publication in JAMA of practice-changing findings from the
U01-funded Kids-DOTT randomized trial on duration of anticoagulation for acute VTE in patients < 21 years old,
and have also generated published evidence on several subpopulation-specific RAMs over the past 3 years.
Yet, critical knowledge gaps remain regarding RAM development in critically ill patients and the investigation of
prognostic markers for clinically-important VTE outcomes, including recurrent VTE and PTS. In this K24
proposal, I will mentor six junior faculty clinical/translational researchers focused in VTE prevention and
treatment, from across four pediatric disciplines (hematology, critical care medicine, hospital medicine,
pharmacy) and three academic institutions (Johns Hopkins University [JHU], University of Alabama at
Birmingham, Harvard University), including three females and three individuals of color or historically
underrepresented backgrounds. The proposed studies build upon existing collaborations in data science and
biomarker-informed prognostic modeling, and will leverage data and/or biospecimens from multicenter studies
in which I play a leadership or senior collaborating role. In each project, the junior faculty mentee will also have
direct interaction with new or existing patients on study, for de novo data collection. Under this K24 proposal, I
will enhance my mentorship expertise via the JHU Master Mentor Program and grow my knowledge in both
Bayesian methods and plasma proteomics through online coursework and regular interactions with experts in
these fields, who also serve as co-investigators in the proposed projects. By facilitating the expansion of my
interdisciplinary research in pediatric VTE and strengthening my abilities to successfully mentor future junior
faculty clinical and translational researchers in the field of pediatric VTE from across a range of disciplines and
institutions, the proposed K24 will have significant impact as a force-multiplier in the pediatric VTE field.

## Key facts

- **NIH application ID:** 10738954
- **Project number:** 1K24HL166791-01A1
- **Recipient organization:** JOHNS HOPKINS UNIVERSITY
- **Principal Investigator:** NEIL A GOLDENBERG
- **Activity code:** K24 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $128,799
- **Award type:** 1
- **Project period:** 2024-02-15 → 2029-01-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10738954

## Citation

> US National Institutes of Health, RePORTER application 10738954, Mentorship in Investigating Novel Risk Models and Prognostic Factors in Patients Less Than 21 Years Old with Venous Thromboembolism (1K24HL166791-01A1). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/10738954. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*